Literature DB >> 8415896

EEG alterations and seizures during treatment with clozapine. A retrospective study of 283 patients.

W Günther1, T Baghai, D Naber, R Spatz, H Hippius.   

Abstract

In a retrospective study, 1863 EEG recordings made during clozapine treatment of 283 patients with normal pretreatment EEG evaluations were analyzed. Furthermore, they were compared to the EEGs of the same patients without clozapine (i.e., during other neuroleptic medication). Moreover, the data of all patients who had seizures during treatment with clozapine were evaluated in case reports. Classical clinical EEG evaluation criteria for normal versus abnormal were used (including diffuse slowing and grouped alterations according to Jung 1953 and Kugler 1983). Of the 283 patients investigated, 61.5% (174) showed at least one abnormal EEG under clozapine according to these criteria. Evaluating all recorded EEGs of these patients in order to get some longitudinal information, we found a rate of 53.4% abnormal EEG recordings during clozapine treatment. Most of the EEG changes were evaluated as slight (22.5%) to moderate (10.1%) diffuse slowing and some as groups of nonparoxysmal waves (39.8%) or sharp waves (16.2%) rendering the EEGs abnormal according to the above criteria. Potential signs of increased bioelectrical cerebral reagibility such as paroxysmal activity (4.3%) or severe diffuse slowing (0.2%) were rare. A nearly linear correlation with the daily dose was found in the range up to 300 mg clozapine/day for both diffuse and grouped alterations. Possibly due to selection, adaptive mechanisms/habituation, and/or other unknown factors, the rate of alterations decreased slightly at doses above 300 mg and rose again sharply for doses over 600 mg/d. Three of the clozapine-treated patients, equivalent to 1.1%, developed seizures.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8415896     DOI: 10.1055/s-2007-1014345

Source DB:  PubMed          Journal:  Pharmacopsychiatry        ISSN: 0176-3679            Impact factor:   5.788


  10 in total

1.  Sleep Homeostatic and Waking Behavioral Phenotypes in Egr3-Deficient Mice Associated with Serotonin Receptor 5-HT2 Deficits.

Authors:  Janne Grønli; William C Clegern; Michelle A Schmidt; Rahmi S Nemri; Michael J Rempe; Amelia L Gallitano; Jonathan P Wisor
Journal:  Sleep       Date:  2016-12-01       Impact factor: 5.849

Review 2.  Drug-induced seizures in the elderly. Causative agents and optimal management.

Authors:  K L Franson; D P Hay; V Neppe; W Y Dahdal; W U Mirza; G T Grossberg; D M Chatel; P A Szwabo; S Kotegal
Journal:  Drugs Aging       Date:  1995-07       Impact factor: 3.923

3.  Clozapine-related EEG changes and seizures: dose and plasma-level relationships.

Authors:  Seema Varma; Delia Bishara; Frank M C Besag; David Taylor
Journal:  Ther Adv Psychopharmacol       Date:  2011-04

4.  Risk of seizures associated with antipsychotic treatment in pediatrics with psychiatric disorders: a nested case-control study in Korea.

Authors:  Soo Min Jeon; Susan Park; Dohoon Kim; Jin-Won Kwon
Journal:  Eur Child Adolesc Psychiatry       Date:  2020-04-07       Impact factor: 4.785

5.  Electroencephalographic abnormalities in clozapine-treated patients: a cross-sectional study.

Authors:  Nishant Goyal; Samir Kumar Praharaj; Pushpal Desarkar; Haque Nizamie
Journal:  Psychiatry Investig       Date:  2011-12-08       Impact factor: 2.505

6.  Clozapine-induced seizures, electroencephalography abnormalities, and clinical responses in Japanese patients with schizophrenia.

Authors:  Yuka Sugawara Kikuchi; Wataru Sato; Keiichiro Ataka; Kiwamu Yagisawa; Yuki Omori; Takashi Kanbayashi; Tetsuo Shimizu
Journal:  Neuropsychiatr Dis Treat       Date:  2014-10-15       Impact factor: 2.570

7.  Low-dose Clozapine-induced Seizure: A Case Report.

Authors:  Abdullah Bolu; Süleyman Akarsu; Erdal Pan; Emre Aydemir; Taner Oznur
Journal:  Clin Psychopharmacol Neurosci       Date:  2017-05-31       Impact factor: 2.582

Review 8.  Clozapine Monitoring in Clinical Practice: Beyond the Mandatory Requirement.

Authors:  Nilamadhab Kar; Socorro Barreto; Rahul Chandavarkar
Journal:  Clin Psychopharmacol Neurosci       Date:  2016-11-30       Impact factor: 2.582

Review 9.  A Framework Proposal to Follow-Up on Preclinical Convulsive Signals of a New Molecular Entity in First-in-Human Studies Using Electroencephalographic Monitoring.

Authors:  Markus Abt; Theo Dinklo; Andreas Rothfuss; Elisabeth Husar; Robert Dannecker; Katja Kallivroussis; Richard Peck; Lucette Doessegger; Christoph Wandel
Journal:  Clin Pharmacol Ther       Date:  2019-05-31       Impact factor: 6.875

10.  Clozapine-induced seizure.

Authors:  Ankur Jyoti Borah; Abhijit Kalita; Satya Kumar Dutta
Journal:  Indian J Pharmacol       Date:  2020-01-16       Impact factor: 1.200

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.